Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORY-1001 plus platinum-etoposide in relapsed extensive-stage small cell lung cancer
2018-000469-35Phase 2Completed
- Sponsor
- Oryzon Genomics
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iadademstat in small cell lung cancer (SCLC), sponsored by Oryzon Genomics. Primary endpoint: Safety, tolerability and dose finding of combination therapy. Started Aug 2018; status: completed.
02
Drugs
iadademstat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2018-000469-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000469-35.